The FDA’s Medical Imaging Drugs Advisory Committee will meet on Thursday, April 23, to review and discuss the marketing application from Eli Lilly (NYSE:LLY) unit Avid Radiopharmaceuticals seeking approval of radiographic diagnostic agent flortaucipir F18 for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of tau protein aggregates associated with Alzheimer’s disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.